Repare Therapeutics (RPTX) News Today $1.04 -0.03 (-2.34%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeedsApril 1 at 4:04 AM | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)April 1 at 4:04 AM | markets.businessinsider.comRepare Therapeutics Names Forte as President, CEOMarch 31 at 6:02 PM | marketwatch.comRepare Therapeutics Announces Leadership TransitionsMarch 31 at 4:39 PM | businesswire.comHC Wainwright Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $5.00HC Wainwright decreased their target price on shares of Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating for the company in a research note on Friday.March 8, 2025 | marketbeat.comRepare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | businesswire.comRepare Therapeutics price target lowered to $5 from $10 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comHere's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn SituationMarch 4, 2025 | uk.finance.yahoo.comRepare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 4, 2025 | finance.yahoo.comRepare Therapeutics reports Q4 EPS (67c), consensus (79c)March 3, 2025 | markets.businessinsider.comLifeSci Capital Sticks to Its Hold Rating for Repare Therapeutics (RPTX)March 3, 2025 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSRepare Therapeutics (NASDAQ:RPTX - Get Free Report) released its earnings results on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%.March 3, 2025 | marketbeat.comRepare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | businesswire.comARK Investment Management LLC Cuts Stock Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX)ARK Investment Management LLC lowered its stake in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 20.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,999,997 shares of the company's stock after sFebruary 27, 2025 | marketbeat.comLifeSci Capital Remains a Hold on Repare Therapeutics (RPTX)February 26, 2025 | markets.businessinsider.comCambridge-Montreal biotech lets go 75% of employeesFebruary 25, 2025 | bizjournals.comRepare Therapeutics (RPTX) Expected to Announce Quarterly Earnings on WednesdayRepare Therapeutics (NASDAQ:RPTX) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comRepare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market ChallengesJanuary 23, 2025 | msn.comShort Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3%Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,300,000 shares, a growth of 53.3% from the December 15th total of 847,800 shares. Currently, 4.3% of the shares of the company are short sold. Based on an average trading volume of 380,100 shares, the days-to-cover ratio is currently 3.4 days.January 17, 2025 | marketbeat.comStrategic Shift and Uncertainties Lead to Hold Rating for Repare TherapeuticsJanuary 12, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Repare Therapeutics (RPTX)January 10, 2025 | markets.businessinsider.comRepare Therapeutics (RPTX) Gets a Hold from LifeSci CapitalJanuary 10, 2025 | markets.businessinsider.comRepare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost ReductionsJanuary 9, 2025 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX) and Centene (CNC)December 16, 2024 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Stock, Insider Trading ActivityDecember 15, 2024 | benzinga.comRepare Therapeutics (NASDAQ:RPTX) Stock, Short Interest ReportDecember 14, 2024 | benzinga.comRepare Therapeutics (NASDAQ:RPTX) Stock Quotes, Forecast and News SummaryDecember 14, 2024 | benzinga.comHold Rating on Repare Therapeutics Amid Mixed Trial Results and Anemia ConcernsDecember 14, 2024 | markets.businessinsider.comLifeSci Capital Downgrades Repare Therapeutics (RPTX)December 14, 2024 | msn.comRepare Therapeutics (NASDAQ:RPTX) Receives Market Perform Rating from Lifesci CapitalLifesci Capital reiterated a "market perform" rating on shares of Repare Therapeutics in a research note on Friday.December 13, 2024 | marketbeat.comRepare Therapeutics Shares Drop 38% Following Phase 1 Trial ResultsDecember 13, 2024 | ca.finance.yahoo.comWhy Is Repare Therapeutics Stock Trading Lower On Friday?December 13, 2024 | uk.finance.yahoo.comWhy Is Repare Therapeutics Stock Trading Lower On Friday?December 13, 2024 | benzinga.comStifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00Stifel Nicolaus decreased their price target on Repare Therapeutics from $9.00 to $4.00 and set a "buy" rating for the company in a report on Friday.December 13, 2024 | marketbeat.comRepare Therapeutics reports ‘positive’ results from MYTHIC Phase 1 trialDecember 12, 2024 | markets.businessinsider.comRepare stock tanks 38% after Phase 1 data releaseDecember 12, 2024 | msn.comRepare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical TrialDecember 12, 2024 | businesswire.comRepare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical TrialDecember 10, 2024 | financialpost.comRepare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical TrialDecember 10, 2024 | businesswire.comRepare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of CamonsertibNovember 13, 2024 | finance.yahoo.comMorgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)November 13, 2024 | markets.businessinsider.comIndustry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue ForecastsNovember 13, 2024 | finance.yahoo.comRepare Therapeutics: Promising Oncology Advances and Financial Stability Support Buy RatingNovember 11, 2024 | markets.businessinsider.comRepare Therapeutics (NASDAQ:RPTX) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Repare Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRepare Therapeutics: Strategic Clinical Advancements and Promising Data Drive ‘Buy’ RatingNovember 8, 2024 | markets.businessinsider.comRepare Therapeutics Reports Q3 2024 Progress and OutlookNovember 8, 2024 | markets.businessinsider.comRepare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comRepare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical OutcomesOctober 25, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Repare Therapeutics (RPTX)October 25, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Repare Therapeutics (NASDAQ:RPTX)HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Thursday.October 24, 2024 | marketbeat.com Remove Ads Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address RPTX Media Mentions By Week RPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPTX News Sentiment▼-0.160.57▲Average Medical News Sentiment RPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPTX Articles This Week▼42▲RPTX Articles Average Week Remove Ads Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MediWound News Molecular Partners News Aclaris Therapeutics News Korro Bio News DiaMedica Therapeutics News Neumora Therapeutics News RAPT Therapeutics News Aardvark Therapeutics News Lyell Immunopharma News Protara Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPTX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RPTX Stock Free RPTX Stock Alerts